Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 349

1.

Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW.

J Hepatol. 2019 May 13. pii: S0168-8278(19)30278-8. doi: 10.1016/j.jhep.2019.04.016. [Epub ahead of print]

PMID:
31096006
2.

Liver Disease Due to Alpha-1 Antitrypsin Deficiency: Are We Surprised That It Is More Complex Than We Thought?

Di Bisceglie AM, Teckman J.

Hepatology. 2019 May 6. doi: 10.1002/hep.30694. [Epub ahead of print] No abstract available.

PMID:
31058323
3.

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104. [Epub ahead of print]

PMID:
30974509
4.

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Feb 8. pii: S1542-3565(19)30143-0. doi: 10.1016/j.cgh.2019.02.005. [Epub ahead of print]

PMID:
30743006
5.

Meet Your President: Michael W. Fried, M.D., F.A.A.S.L.D.

Di Bisceglie AM.

Hepatology. 2019 Apr;69(4):1369-1371. doi: 10.1002/hep.30505. Epub 2019 Mar 20. No abstract available.

PMID:
30653698
6.

HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition.

Brouwer WP, Zhao Q, Hansen BE, Lau D, Khalili M, Terrault NA, Di Bisceglie AM, Perrillo RP, Fried MW, Wong D, Feld JJ, Belle SH, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Jan 7. pii: S1542-3565(19)30012-6. doi: 10.1016/j.cgh.2018.12.039. [Epub ahead of print]

PMID:
30630104
7.

Prevention of hepatocellular carcinoma with antiviral therapy.

Di Bisceglie AM.

S Afr Med J. 2018 Aug 8;108(8b):47-50. doi: 10.7196/SAMJ.2018.v108i8b.13501.

8.

A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.

Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW.

PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018.

9.

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW.

Aliment Pharmacol Ther. 2018 Apr;47(7):1001-1011. doi: 10.1111/apt.14531. Epub 2018 Jan 29.

10.

Template-dependent multiple displacement amplification for profiling human circulating RNA.

Wang W, Ren Y, Lu Y, Xu Y, Crosby SD, Di Bisceglie AM, Fan X.

Biotechniques. 2017 Jul 1;63(1):21-27. doi: 10.2144/000114566.

11.

Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells".

Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB.

J Virol. 2017 Apr 28;91(10). pii: e00349-17. doi: 10.1128/JVI.00349-17. Print 2017 May 15. No abstract available.

12.

Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.

Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM.

Contemp Clin Trials. 2017 Jun;57:58-68. doi: 10.1016/j.cct.2017.03.013. Epub 2017 Mar 22.

13.

Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells.

Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB.

J Virol. 2017 Feb 28;91(6). pii: e02225-16. doi: 10.1128/JVI.02225-16. Print 2017 Mar 15. Erratum in: J Virol. 2017 Apr 28;91(10 ):.

14.

Determination of hepatitis B phenotype using biochemical and serological markers.

Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2017 Apr;24(4):320-329. doi: 10.1111/jvh.12643. Epub 2016 Dec 5.

15.

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group.

Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28.

16.

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group.

Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.

17.

Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities.

Devhare PB, Steele R, Di Bisceglie AM, Kaplan DE, Ray RB.

Gene Expr. 2017 Feb 10;17(2):89-98. doi: 10.3727/105221616X693594. Epub 2016 Oct 19.

PMID:
27765085
18.

Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Kwon YC, Kim H, Meyer K, Di Bisceglie AM, Ray R.

J Immunol. 2016 Aug 15;197(4):1127-36. doi: 10.4049/jimmunol.1600631. Epub 2016 Jun 29.

19.

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.

Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW.

Clin Infect Dis. 2016 Sep 15;63(6):776-783. doi: 10.1093/cid/ciw387. Epub 2016 Jun 19.

20.

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E.

J Viral Hepat. 2016 Aug;23(8):614-22. doi: 10.1111/jvh.12527. Epub 2016 Mar 9.

PMID:
26957110
21.

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Landis CS, Ghabril M, Rustgi V, Di Bisceglie AM, Maliakkal B, Rockey DC, Vierling JM, Bajaj J, Rowell R, Santoro M, Enriquez A, Jurek M, Mokhtarani M, Coakley DF, Scharschmidt BF.

Dig Dis Sci. 2016 Jun;61(6):1728-34. doi: 10.1007/s10620-016-4031-7. Epub 2016 Jan 19.

PMID:
26781427
22.

Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma.

Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB.

Am J Pathol. 2016 Feb;186(2):242-7. doi: 10.1016/j.ajpath.2015.10.003.

23.

Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.

Ren Y, Wang W, Zhang X, Xu Y, Di Bisceglie AM, Fan X.

J Gen Virol. 2016 Feb;97(2):334-43. doi: 10.1099/jgv.0.000346. Epub 2015 Nov 18.

24.

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.

Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA; Hepatitis C Therapeutic Registry Research Network Study Group.

Liver Transpl. 2016 Jan;22(1):24-33. doi: 10.1002/lt.24366.

25.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group.

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

26.

Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.

Kwon YC, Bose SK, Steele R, Meyer K, Di Bisceglie AM, Ray RB, Ray R.

J Virol. 2015 Nov;89(22):11549-56. doi: 10.1128/JVI.01946-15. Epub 2015 Sep 9.

27.

Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.

Lin J, Wang W, Xu Y, Di Bisceglie AM, Fan X.

J Med Virol. 2015 May;87(5):821-8. doi: 10.1002/jmv.24120. Epub 2015 Feb 4.

PMID:
25652546
28.

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM.

Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. doi: 10.1111/apt.13095. Epub 2015 Jan 28.

29.

Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.

Mukherjee A, Di Bisceglie AM, Ray RB.

J Virol. 2015 Mar;89(6):3356-65. doi: 10.1128/JVI.03085-14. Epub 2015 Jan 14.

30.

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH.

Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609. Review.

31.

Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.

Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS; Hepatitis B Research Network; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):183-92. doi: 10.1016/j.cgh.2014.06.028. Epub 2014 Jul 8.

32.

Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components.

Kim H, Meyer K, Di Bisceglie AM, Ray R.

PLoS One. 2014 Jul 1;9(7):e101422. doi: 10.1371/journal.pone.0101422. eCollection 2014.

33.

High-resolution quantification of hepatitis C virus genome-wide mutation load and its correlation with the outcome of peginterferon-alpha2a and ribavirin combination therapy.

Wang W, Zhang X, Xu Y, Weinstock GM, Di Bisceglie AM, Fan X.

PLoS One. 2014 Jun 20;9(6):e100131. doi: 10.1371/journal.pone.0100131. eCollection 2014.

34.

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.

Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):761-73. doi: 10.1097/MEG.0000000000000084.

PMID:
24901821
35.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.

N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

36.

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators.

N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.

37.

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.

N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.

38.

Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.

Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspé G, Agathon D, Limacher JM, Wedemeyer H.

Gastroenterology. 2014 Jul;147(1):119-131.e3. doi: 10.1053/j.gastro.2014.03.007. Epub 2014 Mar 18.

PMID:
24657484
39.

A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables.

Wang M, Mehta A, Block TM, Marrero J, Di Bisceglie AM, Devarajan K.

BMC Med Genomics. 2013;6 Suppl 3:S9. doi: 10.1186/1755-8794-6-S3-S9. Epub 2013 Nov 11. Erratum in: BMC Med Genomics. 2013;6 Suppl 3:S11.

40.

Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet?

Di Bisceglie AM.

Clin Gastroenterol Hepatol. 2014 May;12(5):894-6. doi: 10.1016/j.cgh.2013.11.027. Epub 2013 Dec 4. No abstract available.

41.

Improved biomarker performance for the detection of hepatocellular carcinoma by inclusion of clinical parameters.

Wang M, Block TM, Marrero J, Di Bisceglie AM, Devarajan K, Mehta A.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2012 Dec;2012. doi: 10.1109/BIBM.2012.6392612.

42.

Viral categorization and discovery in human circulation by transcriptome sequencing.

Wang W, Zhang X, Xu Y, Di Bisceglie AM, Fan X.

Biochem Biophys Res Commun. 2013 Jul 5;436(3):525-9. doi: 10.1016/j.bbrc.2013.05.139. Epub 2013 Jun 11.

43.

Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection.

Lamontagne A, Long RE, Comunale MA, Hafner J, Rodemich-Betesh L, Wang M, Marrero J, Di Bisceglie AM, Block T, Mehta A.

PLoS One. 2013 Jun 4;8(6):e64992. doi: 10.1371/journal.pone.0064992. Print 2013.

44.

Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.

Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Diamond MS, Atkinson JP, Ray R.

J Virol. 2013 Jul;87(14):7902-10. doi: 10.1128/JVI.00917-13. Epub 2013 May 8.

45.

Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus.

Lu Y, Xu Y, Di Bisceglie AM, Fan X.

J Virol Methods. 2013 Aug;191(2):105-12. doi: 10.1016/j.jviromet.2013.04.010. Epub 2013 Apr 17.

46.

Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.

Kim H, Meyer K, Di Bisceglie AM, Ray R.

J Virol. 2013 May;87(10):5858-67. doi: 10.1128/JVI.00174-13. Epub 2013 Mar 13.

47.

Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.

Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Martín A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM.

J Clin Gastroenterol. 2013 Oct;47(9):786-93. doi: 10.1097/MCG.0b013e31827b9b45.

PMID:
23442834
48.

Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression.

Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB.

Hepatology. 2013 Sep;58(3):863-71. doi: 10.1002/hep.26296. Epub 2013 Jul 23.

49.

Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes.

Bose SK, Meyer K, Di Bisceglie AM, Ray RB, Ray R.

J Virol. 2012 Dec;86(24):13621-8. doi: 10.1128/JVI.02016-12. Epub 2012 Oct 3.

50.

Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.

Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB.

J Virol. 2012 Sep;86(18):10221-5. doi: 10.1128/JVI.00882-12. Epub 2012 Jul 11.

Supplemental Content

Loading ...
Support Center